- Home
- CANF vs LUXH Comparison
CANF vs LUXH Comparison
Compare CANF & LUXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- LUXH
- Stock Information
- Founded
- CANF 1994
- LUXH 2017
- Country
- CANF Israel
- LUXH United States
- Employees
- CANF N/A
- LUXH N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- LUXH Real Estate
- Sector
- CANF Health Care
- LUXH Finance
- Exchange
- CANF Nasdaq
- LUXH Nasdaq
- Market Cap
- CANF 14.4M
- LUXH 12.7M
- IPO Year
- CANF N/A
- LUXH N/A
- Fundamental
- Price
- CANF $2.46
- LUXH $0.05
- Analyst Decision
- CANF Strong Buy
- LUXH Buy
- Analyst Count
- CANF 2
- LUXH 3
- Target Price
- CANF $14.00
- LUXH $10.00
- AVG Volume (30 Days)
- CANF 137.2K
- LUXH 20.5M
- Earning Date
- CANF 11-15-2024
- LUXH 11-06-2024
- Dividend Yield
- CANF N/A
- LUXH N/A
- EPS Growth
- CANF N/A
- LUXH N/A
- EPS
- CANF N/A
- LUXH N/A
- Revenue
- CANF $667,000.00
- LUXH $90,865,323.00
- Revenue This Year
- CANF $356.93
- LUXH N/A
- Revenue Next Year
- CANF N/A
- LUXH $15.51
- P/E Ratio
- CANF N/A
- LUXH N/A
- Revenue Growth
- CANF N/A
- LUXH 14.73
- 52 Week Low
- CANF $1.81
- LUXH $0.05
- 52 Week High
- CANF $4.69
- LUXH $6.88
- Technical
- Relative Strength Index (RSI)
- CANF 62.91
- LUXH 34.05
- Support Level
- CANF $1.87
- LUXH $0.05
- Resistance Level
- CANF $2.55
- LUXH $0.08
- Average True Range (ATR)
- CANF 0.17
- LUXH 0.01
- MACD
- CANF 0.06
- LUXH -0.00
- Stochastic Oscillator
- CANF 85.94
- LUXH 3.45
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About LUXH LuxUrban Hotels Inc.
LuxUrban Hotels Inc utilizes a long term lease, asset-light business model to acquire and manage a growing portfolio of short-term rental properties in metropolitan cities. It identifies, acquires, manages, and markets hotel rooms to business and vacation travelers under the consumer brand, LuxUrban. It manages a portfolio of hotel rooms in New York, Washington D.C., Miami Beach, New Orleans and Los Angeles.